Interferon alpha concentrations in blood and peritoneal fluid during treatment for hepatitis C.
作者信息
Smirne C, Minisini R, Burlone M E, Ceriani E, Corlianò F, Occhino G, Pirisi M
出版信息
Perit Dial Int. 2012 Nov-Dec;32(6):664-6. doi: 10.3747/pdi.2011.00307.
Abstract
摘要
相似文献
1
Interferon alpha concentrations in blood and peritoneal fluid during treatment for hepatitis C.丙型肝炎治疗期间血液和腹水中的α干扰素浓度。
Perit Dial Int. 2012 Nov-Dec;32(6):664-6. doi: 10.3747/pdi.2011.00307.
2
Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.患者摘要。聚乙二醇化干扰素联合或不联合利巴韦林用于接受血液透析的丙型肝炎患者。
Ann Intern Med. 2013 Dec 3;159(11):I-14. doi: 10.7326/0003-4819-159-11-201312030-00001.
3
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.聚乙二醇干扰素α-2a 联合或不联合小剂量利巴韦林治疗初治丙型肝炎病毒基因型 1 接受血液透析的患者：一项随机试验。
Ann Intern Med. 2013 Dec 3;159(11):729-38. doi: 10.7326/0003-4819-159-11-201312030-00005.
4
Difficult management of triple therapy for chronic hepatitis C in a patient on haemodialysis.血液透析患者慢性丙型肝炎三联疗法的管理难题
Gastroenterol Hepatol. 2017 May;40(5):356-358. doi: 10.1016/j.gastrohep.2016.02.012. Epub 2016 Apr 3.
5
[Treatment of infection due to hepatitis C virus in haemodialysis].[血液透析中丙型肝炎病毒感染的治疗]
Nefrologia. 2014;34(1):132-3. doi: 10.3265/Nefrologia.pre2013.Sep.12268.
6
Treatment of HCV-related liver disease in the dialysis population: a novel challenge for clinical nephrologists.透析人群中丙型肝炎病毒相关肝病的治疗：临床肾脏病医生面临的新挑战。
Int J Artif Organs. 2001 Jun;24(6):335-46.
7
Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.聚乙二醇干扰素 α-2a 治疗血液透析患者慢性 HCV 感染：沙特单一中心经验。
Int Urol Nephrol. 2011 Sep;43(3):865-73. doi: 10.1007/s11255-010-9756-1. Epub 2010 May 19.
8
[High dose of pegylated interferon alpha-2a for the treatment of genotype1 chronic hepatitis C: a case report].[大剂量聚乙二醇化干扰素α-2a治疗基因1型慢性丙型肝炎：1例报告]
Zhonghua Gan Zang Bing Za Zhi. 2010 Nov;18(11):873. doi: 10.3760/cma.j.issn.1007-3418.2010.11.025.
9
What are the management issues for hepatitis C in dialysis patients?: hepatitis C virus infection and its treatment in patients with end-stage renal disease.透析患者丙型肝炎的管理问题有哪些？：终末期肾病患者的丙型肝炎病毒感染及其治疗
Semin Dial. 2014 Sep-Oct;27(5):451-5. doi: 10.1111/sdi.12290.
10
[Treatment of chronic hepatitis C with pegylated alpha-interferons].聚乙二醇化α干扰素治疗慢性丙型肝炎
Dtsch Med Wochenschr. 2002 Mar 15;127(11):563-6. doi: 10.1055/s-2002-22049.
引用本文的文献
1
Expressing Type I Interferon From Atlantic Salmon Enhances the Innate Antiviral Immune Response and .从大西洋三文鱼中表达 I 型干扰素增强了先天抗病毒免疫反应 和 。
Front Immunol. 2021 Aug 12;12:696781. doi: 10.3389/fimmu.2021.696781. eCollection 2021.
本文引用的文献
1
Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C.聚乙二醇化干扰素α-2a单药治疗一名慢性丙型肝炎腹膜透析患者
NDT Plus. 2008 Aug;1(4):233-5. doi: 10.1093/ndtplus/sfn069. Epub 2008 Jun 5.
2
[A case of pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C].[聚乙二醇化干扰素α-2a单药治疗腹膜透析慢性丙型肝炎患者1例]
Korean J Gastroenterol. 2011 Dec;58(2):107-10. doi: 10.4166/kjg.2011.58.2.107.
3
Comparing survival between peritoneal dialysis and hemodialysis treatment in ESRD patients with chronic hepatitis C infection.比较慢性丙型肝炎感染的终末期肾病患者中腹膜透析和血液透析治疗的生存率。
Perit Dial Int. 2010 Jan-Feb;30(1):86-90.
4
Diagnosis, management, and treatment of hepatitis C: an update.丙型肝炎的诊断、管理与治疗：最新进展
Hepatology. 2009 Apr;49(4):1335-74. doi: 10.1002/hep.22759.
5
Treatment predictors of a sustained virologic response in hepatitis B and C.乙型和丙型肝炎病毒持续病毒学应答的治疗预测因素
J Hepatol. 2008 Oct;49(4):634-51. doi: 10.1016/j.jhep.2008.07.013. Epub 2008 Jul 31.
6
KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease.KDIGO慢性肾脏病丙型肝炎预防、诊断、评估及治疗临床实践指南。
Kidney Int Suppl. 2008 Apr(109):S1-99. doi: 10.1038/ki.2008.81.
7
The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment.丙型肝炎感染的肾移植受者：移植前和移植后的治疗
Clin J Am Soc Nephrol. 2007 May;2(3):563-75. doi: 10.2215/CJN.02930806. Epub 2007 Mar 14.
8
Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection.聚乙二醇化干扰素-α 2a用于慢性丙型肝炎病毒感染透析患者的初步研究。
Nephrology (Carlton). 2007 Feb;12(1):11-7. doi: 10.1111/j.1440-1797.2006.00662.x.
9
Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications.α干扰素-2b在接受慢性血液透析或肾功能正常的慢性丙型肝炎病毒患者中的药代动力学：临床意义。
J Am Soc Nephrol. 1998 Dec;9(12):2344-8. doi: 10.1681/ASN.V9122344.
10
The preclinical development of Roferon-A.罗扰素A的临床前研发。
Cancer. 1986 Apr 15;57(8 Suppl):1648-56. doi: 10.1002/1097-0142(19860415)57:8+<1648::aid-cncr2820571303>3.0.co;2-o.
Zotero 插件